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Executive Summary
On October 8, 2008, the President signed the ALS Registry Act (Public Law No. 110-373) into law. It authorizes the Centers for Disease Control and Prevention (CDC) to establish a national amyotrophic lateral sclerosis (ALS) patient registry to identify ALS cases in the United States. The Agency for Toxic Substances and Disease Registry (ATSDR) has already begun to create the building blocks for this national registry by finding partners to pilot projects that would provide information for developing strategies to identify patients and highlight best practices in data sharing and acquisition.
In November, ATSDR requested partnership with CSTE in assessing all existing state chronic neurologic disease surveillance systems, specifically concerning ALS. In collaboration with ATSDR and several CSTE member epidemiologists, CSTE created an assessment to be sent to the states.
Nine (18%) states reported currently conducting surveillance for neurologic diseases. Only South Carolina conducted surveillance for all of the chronic neurologic diseases. Two states each reported conducting surveillance for only one neurologic disease: Alzheimer's disease (South Dakota) and ALS (Massachusetts).
This report compiles results of the assessment conducted by CSTE about the surveillance of chronic neurologic diseases, including ALS, by state. All information was provided by state health department staff specializing in chronic disease or environmental health epidemiology. The results should prove useful in determining the geographic distribution of surveillance activities and the legal impetus for surveillance; identifying the type of noninfectious, nontraumatic neurologic disease surveillance conducted by states; and providing further information about state programs associated with ALS surveillance.
Introduction
The Council of State and Territorial Epidemiologists (CSTE) promotes the effective use of epidemiologic data to guide public health practice and improve health. CSTE accomplishes this by supporting the use of effective public health surveillance and good epidemiologic practice through training, capacity development, and peer consultation; developing standards for practice; and advocating science-based policy.
Senate Bill 1353 amends the Public Health Service Act to provide for the establishment of an amyotrophic lateral sclerosis (ALS) patient registry. The ALS Registry Act amends the Public Health Service Act to require the Director of the Centers for Disease Control and Prevention (CDC) to 1) develop a system to collect data on ALS and 2) establish a national registry for the collection and storage of ALS data.
On October 8, 2008, the President signed the ALS Registry Act (Public Law No. 110-373) into law. It authorizes the Centers for Disease Control and Prevention (CDC) to establish a national amyotrophic lateral sclerosis (ALS) patient registry to identify ALS cases in the United States.
The aim of a national ALS registry is to use the data collected to help discover the cause of and develop treatments for this fatal neurologic disease. CSTE supports meaningful scientific inquiry and surveillance for chronic neurologic diseases while recognizing that strong national data must be collected through partnerships between state and local health departments. Dissemination of these public health data will arm scientists with the tools necessary to search for a means to mitigate the effects of ALS and to move forward in finding a cure.
In November 2008, the Agency for Toxic Substances and Disease Registry (ATSDR) requested partnership with CSTE in identifying and assessing all existing state neurologic disease surveillance systems, particularly those concerning ALS. This report explains the method of assessment and presents results for the nine states that currently conduct surveillance for chronic neurologic diseases. It also includes information obtained from interviews with epidemiologists in the two states that maintain an ALS disease-specific surveillance system. ATSDR can use the information in this report to help meet the objectives of the ALS Registry Act.
Method of Assessment

Web-Based Assessment
An assessment tool was developed to examine the chronic neurologic disease surveillance activities of states using Survey Monkey (SurveyMonkey.com; 2009). It was administered to the CSTE identified state health department points of contact in chronic disease and environmental health. The assessment consisted of seven questions (Appendix A). Chronic Disease and Environmental Health Epidemiology points of contact that CSTE maintains for each state health department were contacted and instructed to provide one response per state. In the three instances when both points of contact responded to the assessment, follow-up was conducted and discrepancies resolved.
From late February through mid-March 2009, CSTE conducted the ALS State Surveillance Assessment. The assessment asked respondents to indicate whether their state conducted surveillance for chronic neurologic diseases in general and for ALS in particular. States without ALS surveillance systems were asked via the assessment whether they were considering adding surveillance for any chronic neurologic diseases. For states conducting surveillance activities for chronic neurologic diseases, data were collected on specific neurologic diseases and conditions: motor neuron disease (e.g., ALS), multiple sclerosis, Parkinson's disease, Alzheimer's disease, epilepsy, GuillainBarré syndrome, Creutzfeldt-Jakob disease, and other. If a state indicated conducting surveillance for a neurologic disease, follow-up questions were asked to determine whether the disease was a reportable condition and whether there was a state legislative mandate to conduct the surveillance.
Follow-Up Telephone Interview
ATSDR and CSTE collaborated on the questions for a follow-up interview of states that reported conducting ALS surveillance (Appendix B). CSTE epidemiology staff conducted the telephone interviews with the individuals who maintain the surveillance systems. The goal of the telephone interviews was to obtain general information about state surveillance programs and associated activities.
Results
The majority of respondents to the assessment were Chronic Disease and Environmental Health Epidemiology points of contact in each state. Their positions/titles were as follows: chronic disease epidemiologist, branch chief, state epidemiologist, state toxicologist, director of surveillance, chief medical officer, and other. The program areas in which respondents are employed within the Department of Health also varied. In most cases, respondents were the points of contact for the surveillance system. Of the neurologic diseases for which states conduct surveillance, Creutzfeldt-Jakob disease was conducted most often and is the neurologic disease with the most state legislative mandates for its surveillance. Four states reported collecting Alzheimer's disease surveillance information, and four collect Parkinson's disease surveillance information. Three states reported collecting surveillance data for both Alzheimer's disease and Creutzfeldt-Jakob disease.
Surveillance for chronic neurologic disease varied from state to state (Table 1) . Both Delaware and Idaho reported collecting information on Guillian-Barré syndrome and Creutzfeldt-Jakob disease. Only South Carolina conducted surveillance for all of the chronic neurologic diseases. Two states each reported conducting surveillance for only one neurologic disease: Alzheimer's disease (South Dakota) and ALS (Massachusetts). For each of these chronic neurologic diseases, states varied with respect to legislative mandates, the reportability of the diseases, and implementation of surveillance systems ( Massachusetts developed its surveillance system by using information from five studies. The first study determined the prevalence of ALS in southeastern Massachusetts. A second study examined the feasibility of various options for a statewide ALS surveillance system. The third and fourth studies were pilot studies of an ALS registry conducted first in Essex County and then in Boston. The last study examined feedback from focus groups about implementing an ALS surveillance system in Massachusetts. These studies are detailed in the Massachusetts protocol.
Massachusetts learned many lessons from the above studies. One major lesson was the need to identify a method to capture only true ALS cases; unlike for cancer, no central source exists for identifying ALS patients. In addition, ALS often is difficult to diagnose. To address this problem, the Massachusetts registry required a two-stage data abstraction process, as follows: 1) nurses with neurologic training established the eligibility of a case (based on patient residence, date of diagnosis, and certainty of diagnosis) according to the El Escorial diagnostic criteria; and 2) additional clinical information was collected and the diagnosis was confirmed by an independent neurologist according to the criteria of the World Federation of Neurology.
Learning the feasibility of establishing such a registry was valuable. The average length of time for medical record abstraction was 1-3 hours per record, excluding travel time. It is often required that surveillance personnel obtain multiple records from different institutions. Finally, the patients themselves may play an important role in ensuring the completeness of any registry; if ALS advocacy groups publicize the existence of an ALS registry, patients can remind their physicians to submit information.
In addition, Massachusetts had to address legal hurdles. Massachusetts amended some state regulations to encourage reporting of cases and ensure protection of privacy and compliance with the Health Insurance Portability and Accountability Act. An advisory committee was recommended to support the operations of the registry once 
Discussion
Because the initial inquiry about where ALS surveillance activities fall within a given state health department yielded no single answer, CSTE sent the ALS State Surveillance Assessment both to chronic disease and environmental health epidemiology points of contact. The diversity of respondents by department and position title makes a subtle but systemic issue apparent. Every state organizes and manages its health department differently, presenting a potential obstacle in developing state mandates for sharing data on chronic neurologic disease. In most cases, however, the respondent who completed the assessment was the main point of contact for the surveillance system. Any discussions of chronic neurologic disease surveillance should include individuals from at least both of these disciplines.
The processes for developing chronic neurologic disease surveillance in each state seem to vary considerably. The assessment demonstrated that the association between the number of states that conduct any surveillance for chronic neurologic disease and the number of states in which chronic neurologic diseases are reportable or in which surveillance is legislatively mandated is inconclusive. Though states do not need a legislative mandate or a reporting mandate to conduct surveillance, a number of states pursue surveillance regardless. This is exemplified by ALS, Parkinson's disease, Alzheimer's disease, Guillain-Barré syndrome, and Creutzfeld-Jakob disease surveillance. 2 . Yet, the responding audience of the assessment was environmental and chronic disease epidemiology points of contact in state health departments. The SRCA was developed by CDC and CSTE to cover state reporting requirements as defined by regulation or legislation, for all conditions defined as reportable by clinicians (health care providers), laboratories, hospitals, and other reporters at the state level. The SRCA demonstrated that 46 states (92%) report Creutzfeldt-Jakob which is significantly more than the 6 that were identified by our environmental and chronic disease points of contact. This gap was exacerbated by the logic model built into the Survey Monkey assessment which directed any responders who selected "no chronic neurologic disease surveillance" to the end of the assessment. Therefore, responders who did not consider Creutzfeldt-Jakob or perhaps Guillain-Barré syndrome as a chronic neurologic disease would not have even received an opportunity to answer. Discrepancies were also found with Parkinson's Disease and Guillain-Barré syndrome. It is likely that information about Creutzfeldt-Jakob, Guillain Barre, and Parkinson's disease surveillance without the consultation of infectious disease epidemiologists was incomplete. (Note: The SRCA did not include ALS in the list of conditions which states were asked to identify as reportable or not.) Further research would be necessary to classify the reporting rules for these conditions to compare with the results from this assessment.
